Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab Combined With MRG-003 as Neoadjuvant Treatment of EBV- Associated Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-arm, Single-center, Prospective Phase II Trial

NCT07267338 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07267338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07267338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab Combined With MRG-003 as Neoadjuvant Treatment of EBV- Associated Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-arm, Single-center, Prospective Phase II Trial
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2029
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locoregionally advanced nasopharyngeal carcinoma, npc